Navigation Links
Carbapenems and Other Agents that Provide Broad-Spectrum Activity are Preferred by Surveyed Physicians for the Treatment of Intra-Abdominal Infections

A Drug's Activity Against Anaerobes is the Leading Attribute in Antibiotic Selection, According to a New Report from AMR and Decision Resources

MALVERN, Pa. and WALTHAM, Mass., May 27 /PRNewswire/ -- Arlington Medical Resources (AMR) and Decision Resources find that surveyed physicians will increase prescribing of Wyeth's Tygacil, Merck's Invanz and Johnson & Johnson's Doribax in the next five years for the treatment of intra-abdominal infections because of their potent broad-spectrum activity and efficacy against gram-negative and anaerobic organisms.

"Treatment for intra-abdominal infections is largely empiric," stated Lisa Arias, analyst at Decision Resources. "A variety of organisms, particularly gram-negative aerobic bacteria and anaerobes, are documented in patients with an intra-abdominal infection. In fact, the leading attribute that physicians surveyed look for in a drug to treat intra-abdominal infections is its activity against anaerobes."

The new report entitled Hospital Anti-Infectives Insight Series: Intra-Abdominal Infections also finds that 96 percent of surveyed physicians cite a drug's activity against anaerobes as the leading attribute in antibiotic selection. Intra-abdominal infections are often polymicrobial in nature and involve anaerobes specific to the etiology of the infection, so activity against these organisms is advantageous even without bacterial confirmation.

"Physicians also rank availability in intravenous formulation and a low propensity to induce resistance as other important drug attributes that influence their selection in antibiotics," added Ms. Arias. "While some agents with anaerobic and gram negative activity, such as carbapenems, address some of these attributes, no antibiotic captures all of the top most important attributes which leaves opportunity for novel products to differentiate themselves."

About Hospital Anti-Infectives Insight Series

AMR and Decision Resources' Hospital Anti-Infectives Insight Series analyzes hospital antibiotic prescribing patterns using AMR's comprehensive and highly detailed clinical data in conjunction with Decision Resources' disease area knowledge, primary research and extensive understanding of emerging therapies and forecasts. These reports examine the reasons behind physicians' product preferences, factors driving hospital antibiotic prescribing patterns and receptivity to emerging antibiotics.

Members of the media are welcome to attend our upcoming webinar entitled Hospital Anti-Infectives Insight Series: Analyzing Prescribing Trends and Emerging Therapies in the Hospital Antibiotic Market. The webinar will be held on Wednesday, June 17, 2009 at 10 a.m. EDT. For more information, please contact Gisselle Morales at 781.296.2691 or e-mail at

About AMR

AMR ( serves the market intelligence needs of the pharmaceutical and diagnostic imaging industries. Research includes clinical inpatient databases that directly link anti-infective drug with indication/procedure, formulary and stocking status tracking studies, drug purchasing audits and diagnostic imaging procedure volume/contrast media usage audits. AMR is a Decision Resources, Inc. company.

About Decision Resources

Decision Resources ( is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Gisselle Morales                             Elizabeth Marshall
    Decision Resources                           Decision Resources, Inc.
    781-296-2691                                 781-296-2563            

SOURCE Decision Resources; Arlington Medical Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
2. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
3. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
4. Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents
5. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
6. Zila Inc. Product Selected to Identify Pre-Cancer in Study of Leading Cancer Treatment Chemotherapeutic - ERBITUX
7. Advanced Life Sciences to Present Data on Selected Cethromycin Therapeutic Studies at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
8. Tablet PC Technology Helps Doctors and Patients Focus on Chemotherapy Side Effects, According to Thomson Healthcare Study
9. Promising Data from Paratek Pharmaceuticals MAR Inhibitor Program Presented in Late Breaker Session at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
10. New Data Show That GlaxoSmithKlines Rotarix(R) Could Be Given With Other Routine Infant Vaccines in the U.S.
11. Oritavancin Demonstrates Potent and Rapid In Vitro Activity Against MRSA, VRE and Other Strains of Resistant Bacteria
Post Your Comments:
(Date:10/5/2017)... ROSEMONT, Ill. , Oct. 5, 2017 /PRNewswire-USNewswire/ ... American Association of Oral and Maxillofacial Surgeons (AAOMS) ... than opioids – to be used as a ... post-surgical pain. ... relationship, the AAOMS White Paper "Opioid Prescribing: Acute ...
(Date:10/2/2017)... INDIANAPOLIS , Oct. 2, 2017  Eli Lilly ... its financial results for the third quarter of 2017 ... a conference call on that day with the investment ... performance. The conference call will begin at ... public can access a live webcast of the conference ...
(Date:9/28/2017)... Sept. 28, 2017 Cohen Veterans Bioscience and ... use of wearable and home sensors for real-time monitoring ... Signal Foundation, a nonprofit organization focused on disruptive health ... an affordable analytical system to record and integrate behavioral, ... ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... The American Board of Family Medicine's (ABFM) ... and Chief Executive Officer, succeeding Dr. James C. Puffer upon his retirement. Dr. Newton ... until Dr. Puffer’s retirement at the end of 2018. Upon assuming the role of ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Lori R. Somekh, ... member of ElderCounsel, a national organization of elder law and special needs planning attorneys. ... and rules. It also provides a forum to network with elder law attorneys nationwide,” ...
(Date:10/13/2017)... ... 2017 , ... Ellevate Network, the leading network for professional women, brought together ... equality at their inaugural Summit in New York City in June. The event was ... of over 3 million. To watch the Mobilize Women video, click here . ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a ... has been awarded a contract by the Center for Medicare and Medicaid Services ... accelerate the enterprise use of Agile methodologies in a consistent and high value ...
(Date:10/12/2017)... ... 12, 2017 , ... CitiDent and San Francisco dentists, Dr. ... Oventus O2Vent technology. As many as 18 million Americans are estimated to suffer ... Oral appliances can offer significant relief to about 75 percent of people with ...
Breaking Medicine News(10 mins):